What's Fueling The Recent Diagnostics Dealmaking?
Executive Summary
A variety of new players have become active dealmakers around personalized medicine diagnostics tests and services. One way to put these deals in context is to view the acquired assets through the lens of how they are to be deployed. To a large extent, the transactions are being driven by the interests of drugmakers, which are seeking new tools to assist them in clinical trials, thus creating more opportunity for the acquirers to offer clinical development services.